# Rapid-onset extrapyramidal symptoms and tardive dyskinesia following a lithium dose increase in bipolar disorder: a case report - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0197 - Language: en - Last updated: not specified - Page title: Rapid-onset extrapyramidal symptoms and tardive dyskinesia following a lithium dose increase in bipolar disorder: a case report | WCP 2026 Summary > A severe hyperkinetic movement disorder that developed within two weeks of a relatively small lithium dose increase at a therapeutic blood level and persisted… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0197) Bu sayfa, 26. Dünya Psikiyatri Kongresi'nde sunulan çalışmanın yapay zekâ desteğiyle hazırlanmış Türkçe özetidir. Çalışmanın sahibi sunan yazarlardır; atıf için orijinal kaynağa başvurun. EV0197 E-PosterPsikofarmakolojiOlgu sunumu # Rapid-onset extrapyramidal symptoms and tardive dyskinesia following a lithium dose increase in bipolar disorder: a case report RAPID ONSET OF EXTRAPYRAMIDAL SYMPTOMS AND TARDIVE DYSKINESIA FOLLOWING LITHIUM DOSE ESCALATION IN BIPOLAR DISORDER: A CASE REPORT Sunan: Burak Emmiler Ülke: Turkey Kurum: Health Sciences University, Erenköy Mental and Nervous Diseases Training and Research Hospital A severe hyperkinetic movement disorder that developed within two weeks of a relatively small lithium dose increase at a therapeutic blood level and persisted for six months despite drug discontinuation demonstrates that SILENT is not solely associated with toxicity. The aim is to present a case demonstrating that the Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT), a rare and severe complication distinct from lithium's well-known adverse effects, can develop rapidly following a small dose increase. The patient was a 53-year-old woman with a 19-year history of bipolar disorder and two previous hospitalizations, who was being treated with lithium 600 mg/day and extended-release quetiapine 300 mg/day; written informed consent was obtained in accordance with the Declaration of Helsinki. Within two weeks of increasing the lithium dose to 900 mg/day, she developed dysarthria, dysphagia, dyspnea, orofacial dyskinesia, severe gait ataxia, and transient perceptual disturbances. A neurological consultation supported the impression of drug-induced extrapyramidal symptoms (EPS), lithium was tapered and discontinued, and the patient was monitored through serial clinical assessments. Despite a serum lithium level within the therapeutic range (0.77 mmol/L) and complete discontinuation of the drug, extrapyramidal and cerebellar symptoms persisted, and the clinical presentation was considered consistent with SILENT. At the six-month follow-up, involuntary jaw movements and a positive Romberg sign persisted and were considered permanent neurological sequelae. The authors highlight four atypical features of the case: rapid onset; a fulminant course; a presentation involving lower-extremity choreoathetoid movements and involuntary jaw movements, together with marked rigidity and cognitive decline, rather than an isolated fine tremor; and the emergence of these findings at a low daily dose and a therapeutic serum level. In conclusion, the assumption that severe motor complications are solely concentration-dependent should be questioned, neurological monitoring should be performed following dose increases, and the drug should be discontinued early because of the risk of progression to tardive dyskinesia. [Orijinal postere git](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1526) Bu çalışmaya nasıl atıf yapılır? APA 7: Emmiler, B., & Karaci, R. (2026, September 23-26). Rapid onset of extrapyramidal symptoms and tardive dyskinesia following lithium dose escalation in bipolar disorder: a case report [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1526 Vancouver: Emmiler B, Karaci R. Rapid onset of extrapyramidal symptoms and tardive dyskinesia following lithium dose escalation in bipolar disorder: a case report [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/1526 Yazar adları ve başlık biçimi kongre sisteminden otomatik oluşturulmuştur; kullanmadan önce orijinal posterle karşılaştırın. ## Aynı konudan - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [Tüm WCP 2026 özetleri](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0197 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim